Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Stirling Anglian Pharmaceuticals Ltd., Hillington Park Innovation Centre, 1 Ainslie Road, Hillington Park, Glasgow G52 4RU, United Kingdom
Stirlescent 250 mg Effervescent Tablets.
| Pharmaceutical Form |
|---|
|
Effervescent tablets. |
Each tablet contains 250 mg Naproxen.
This medicinal product contains 341.89 mg sodium per effervescent tablet.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Naproxen |
Naproxen is a non-steroidal anti-inflammatory analgesic compound with antipyretic properties as has been demonstrated in classical animal test systems. Naproxen exhibits its anti-inflammatory effect even in adrenalectomised animals, indicating that its action is not mediated through the pituitary-adrenal axis. |
| List of Excipients |
|---|
|
Citric acid |
Polypropylene tube with polyethylene desiccant stopper or laminated aluminium paper foil.
Pack sizes: 10, 12, 15, 20, 24 and 30 effervescent tablets.
Not all pack sizes may be marketed.
Stirling Anglian Pharmaceuticals Ltd., Hillington Park Innovation Centre, 1 Ainslie Road, Hillington Park, Glasgow G52 4RU, United Kingdom
PL 42582/0009
03/12/2015
| Drug | Countries | |
|---|---|---|
| STIRLESCENT | Ireland, Malta, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
